Literature DB >> 11981750

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.

Johnson Y N Lau1, Robert C Tam, T Jake Liang, Zhi Hong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11981750     DOI： 10.1053/jhep.2002.32672

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  64 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Authors:  Jörg Vollmer; Robert Rankin; Hanna Hartmann; Marion Jurk; Ulrike Samulowitz; Tanja Wader; Andrea Janosch; Christian Schetter; Arthur M Krieg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

4.  Hepatitis C Virus Therapy-related Skin Manifestations.

Authors:  Brett E Fortune; Shayla Francis; Lisa M Forman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

5.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 6.  Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors:  Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

7.  Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?

Authors:  Hiroki Takahashi; Mikio Zeniya
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

Review 8.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection.

Authors:  Rie Kubota; Takako Komiyama; Naoki Kumagai; Miyuki Kimijima; Keiko Mitsuki; Junko Uetake; Fumihiko Kaneko; Satoshi Tsunematsu; Kanji Tsuchimoto
Journal:  Hepat Res Treat       Date:  2010-09-08

10.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.